A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Ontology highlight
ABSTRACT: TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.
DISEASE(S): Adenocarcinoma,Tnbc - Triple-negative Breast Cancer,Pancreatic Adenocarcinoma,Triple Negative Breast Neoplasms,Colorectal Cancer,Non Small Cell Lung Cancer,Mesothelioma,Triple Negative Breast Cancer,Pancreatic Cancer,Breast Neoplasms,Neoplasms,Ovarian Cancer,Mesothelioma Peritoneum,Mesotheliomas Pleural,Colorectal Neoplasms,Mesothelioma, Malignant,Cystadenocarcinoma, Serous,Ovarian Neoplasms,Ovarian Serous Adenocarcinoma,Pancreatic Neoplasms,Cholangiocarcinoma,Ovarian Adenocarcinoma
PROVIDER: 2740481 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA